Removal of advanced glycation end products in clinical renal failure by peritoneal dialysis and haemodialysis

2003 ◽  
Vol 31 (6) ◽  
pp. 1394-1396 ◽  
Author(s):  
S. Agalou ◽  
N. Ahmed ◽  
A. Dawnay ◽  
P.J. Thornalley
Keyword(s):  
Renal Failure ◽  
Peritoneal Dialysis ◽  
Blood Plasma ◽  
Advanced Glycation End Products ◽  
Peritoneal Cavity ◽  
Dwell Time ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
In Blood Plasma

AGEs (advanced glycation end products) accumulate markedly in the plasma of human subjects with renal failure. We investigated the efficiency of removal of AGEs from the circulation by PD (peritoneal dialysis) and HD (haemodialysis) therapy. Free AGEs were measured by LC-MS/MS in blood plasma before dialysis, in dialysis fluid effusate after a 2–12 h dwell time in the peritoneal cavity of PD subjects, and in the HD dialysate before and after HD therapy. In clinical uraemia, the concentrations of free AGEs in blood plasma were increased up to 50-fold. For example, levels of MG-H1 (methylglyoxal-derived hydroimidazolone) were: normal controls, 110±46 nM; PD subjects, 1876±676 (P<0.01); HD subjects, 5496±1138 nM (P<0.001). In PD subjects, the AGE concentration in the effusate increased with increasing dwell time, reaching a maximum at a concentration higher than that in plasma for some AGEs at 4–12 h. This may reflect AGE formation in the peritoneal cavity. In HD, AGE concentrations in HD fluid were decreased markedly from the start to the end of a dialysis session, except that levels of the methylglyoxal-derived AGEs N∊-(1-carboxyethyl)lysine and MG-H1, and of pentosidine, remained 5-fold higher than control levels. Inadequate clearance of free AGEs may be linked to the increased risk of cardiovascular disease in patients with renal failure.

Induction of 1,2-Dicarbonyl Compounds, Intermediates in the Formation of Advanced Glycation End-Products, during Heat-Sterilization of Glucose-Based Peritoneal Dialysis Fluids

1999 ◽  
Vol 19 (4) ◽  
pp. 325-333 ◽  
Author(s):  
Casper G. Schalkwijk ◽  
Nynke Posthuma ◽  
Herman J. Ten Brink ◽  
Pieter M. Ter Wee ◽  
Tom Teerlink
Keyword(s):  
Peritoneal Dialysis ◽  
Advanced Glycation End Products ◽  
Dwell Time ◽  
Advanced Glycation ◽  
Fluorescence Excitation ◽  
Dicarbonyl Compounds ◽  
Glycation End Products ◽  
End Products

Objective To study the presence of 1,2-dicarbonyl compounds in peritoneal dialysis (PD) fluids, their concentration in effluents with increasing dwell time, and their role in the formation of advanced glycation end-products (AGEs). Measurements Dicarbonyl compounds in heat- and filter-sterilized PD fluids were quantified by reverse-phase high performance liquid chromatography (HPLC) after derivatization to dimethoxyquinoxaline derivatives. Kinetics of the in vitro formation of AGEs upon incubation of 1,2-dicarbonyl compounds or PD fluids with albumin, with or without aminoguanidine, were measured by AGE fluorescence (excitation/emission wavelengths of 350 nm/430 nm). Patients AGEs and dicarbonyl compounds were measured in effluents collected from standardized 4-hour dwells from 8 continuous cycling peritoneal dialysis patients. Results In PD fluids, 3-deoxyglucosone (3-DG) has been identified as the major dicarbonyl compound formed during the process of heat sterilization. The process also formed glyoxal (GO) and methylglyoxal (MGO), with the amount of 3-DG being approximately 25 – 60 times higher than GO and MGO. When incubated with albumin, the identified 1,2-dicarbonyl compounds rapidly formed AGEs. The formation of AGEs was more pronounced in conventional heat-sterilized PD fluids compared with filter-sterilized PD fluids, and was completely inhibited by aminoguanidine. In effluents, the concentration of MGO, GO, and 3-DG decreased with increasing dwell time, with a concomitant increase in AGE fluorescence. Conclusions The dicarbonyl compounds 3-DG, MGO, and GO are potent promoters of AGE formation. The presence of these and possibly other dicarbonyl compounds formed during heat sterilization of glucose-based PD fluids is, to a large extent, responsible for the in vitro AGE formation by these fluids, as evidenced by the speed of AGE formation in PD fluids and the complete inhibition by aminoguanidine. Because 3-DG, MGO, and GO are rapidly cleared from PD fluids during dialysis, these compounds may contribute to the in vivo AGE formation in PD patients.

Advanced glycation end products, aortic stiffness, and wave reflection in peritoneal dialysis as compared to hemodialysis

2013 ◽  
Vol 46 (4) ◽  
pp. 817-824 ◽  
Author(s):  
Fabrice Mac-Way ◽  
Véronique Couture ◽  
Mihai S. Utescu ◽  
Sophie Ignace ◽  
Sacha A. De Serres ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Advanced Glycation End Products ◽  
Aortic Stiffness ◽  
Wave Reflection ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients

2005 ◽  
Vol 43 (5) ◽  
Author(s):  
Xiaohong Zhang ◽  
Matthias Frischmann ◽  
Rose Kientsch-Engel ◽  
Katharina Steinmann ◽  
Helga Stopper ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Advanced Glycation End Products ◽  
Uremic Toxins ◽  
Dialysis Patients ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
Immunosorbent Assays

AbstractAdvanced glycation end-products are uremic toxins that accumulate in the serum and tissues of patients with chronic renal failure. Here, we established two enzyme-linked immunosorbent assays (ELISAs) for N

Sign in / Sign up

Export Citation Format

Share Document